
Nasafytol®, a food supplement containing curcumin, quercetin, and Vitamin D, was tested in a trial involving hospitalized COVID-19 patients. The study aimed to assess its effects and safety as a supportive treatment alongside standard care. On day 14 or earlier hospital discharge, the two groups showed no difference in clinical condition, fever, or need for oxygen therapy. However, on day 7, the Nasafytol® group had a higher number of discharged patients, with no transfers to the ICU or deaths, in contrast to the Fultium® group.
Like
Save
Share